Seeking Alpha

Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price...

Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price target $21). Analyst Ravi Mehrotra says RPC1063 — the company's "key asset" — has a clinical profile that puts it "in a different 'bucket'" than Novartis' Gilenya when it comes to treating multiple sclerosis.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|